Literature DB >> 1790541

Detection and assessment of insomnia.

C A Czeisler1, G S Richardson.   

Abstract

Insomnia is one of the most common complaints encountered by the primary care physician. Yet, in many cases, physicians treat the symptom of insomnia rather than evaluating and treating the underlying causes of insomnia. Because the subjective complaint of insomnia does not always correlate with evidence of objective sleep disruption, a careful history and evaluation are required. Assessment of the duration of insomnia and quantification of the impact of nocturnal sleep disruption on daytime functioning provide the most reliable indices of severity. Primary insomnia may be due to a number of different causes, such as poor sleep hygiene or circadian rhythm disruption. Insomnia may also be the presenting symptom of other primary sleep disorders, such as sleep apnea syndrome or nocturnal myoclonus, or of a variety of medical or psychiatric illnesses. The treatment of the patient with insomnia should address the underlying cause, when identifiable. When the cause cannot be identified, treatment should be conservative; nonpharmacologic therapies should be used whenever possible. When pharmacologic approaches are indicated, short-acting benzodiazepines should be administered in concordance with strict prescribing guidelines. Frequent follow-up is necessary to ensure continued therapeutic efficacy of the prescribed therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1790541

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

Review 1.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

2.  An approach to long-term sedative-hypnotic use.

Authors:  Azmeh Shahid; Sharon A Chung; Ron Phillipson; Colin M Shapiro
Journal:  Nat Sci Sleep       Date:  2012-04-02

Review 3.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.